Form 4: Kronos Bio Director Roshawn A. Blunt Acquires 34,000 Stock Options
SEC Form 4 Filing
Director Roshawn A. Blunt acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.
Summary
- On June 25, 2024, Roshawn A. Blunt, a director of Kronos Bio, Inc., acquired 34,000 stock options.
- The exercise price of these options is $0.95.
- The options vest upon the earlier of the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.
- The options expire on June 24, 2034.
- Following the transaction, Blunt directly owns 34,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/25/2024 | Date of transaction: Roshawn A. Blunt acquired 34,000 stock options. |
| 06/24/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.